Search - tctmd.com

Displaying 41 - 60 of 176

Sort: Relevancy | Date

Presentation ESC 2019

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Presenter: Deepak Bhatt

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

Presentation Fellows 2019

The Evolution in PCI Pharmacology Over the Past 25 Years

Presenter: Deepak L. Bhatt

April 12, 2019

News Daily News

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

Michael O'Riordan

April 11, 2019

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

News Daily News

Genetic Risk Factor Discovered for Spontaneous Coronary Artery Dissection

Todd Neale

January 18, 2019

News Daily News

SYNTAX Score Should Not Guide Revascularization Strategy in FREEDOM-Like Patients

Michael O'Riordan

December 04, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

Presentation TCT 2018

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

Presenter: Anthony H. Gershlick, Pieter C. Smits, Deepak L. Bhatt

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Giuseppe Biondi-Zoccai

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Kurt Huber

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Advertisement

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

The Evolution in PCI Pharmacology Over the Past 25 Years

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Genetic Risk Factor Discovered for Spontaneous Coronary Artery Dissection

SYNTAX Score Should Not Guide Revascularization Strategy in FREEDOM-Like Patients

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content